🏛️ Verified NIH Record • Updated 2026-03-23
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (NCT04008797)
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Eisai Inc.
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
Who can join: Review the eligibility criteria below.
Location: UAMS — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (106 Sites)
Showing the first 25 of 106 sites.
- UAMS — Little Rock, Arkansas
- University of California San Diego (UCSD) - Moores Cancer Center(All) — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Pasadena Liver Center — Pasadena, California
- California Pacific Medical Center — San Francisco, California
- UCLA University of California - Los Angeles — Santa Monica, California
- John Muir Clinical Research — Walnut Creek, California
- University of Colorado Cancer Center - Anschutz Medical Campus — Aurora, Colorado
- Uni. Of Miami- Sylvester Cancer Centre — Miami, Florida
- Florida Cancer Specialists - South — Sarasota, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
- Women's Cancer Care - Covington, LA — Covington, Louisiana
- University Of Mississippi Medical Center — Jackson, Mississippi
- Kansas City Research Institute — Kansas City, Missouri
- Perlmutter Cancer Center- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center (MMC) - Jack D. Weiler Hospital — The Bronx, New York
- MetroHealth Medical Center — Cleveland, Ohio
- ProMedica Flower Hospital — Sylvania, Ohio
- University of Oklahoma Health Science Center — Oklahoma City, Oklahoma
- Medical University of South Carolina — Charleston, South Carolina
- Sanford Cancer Centre — Sioux Falls, South Dakota
- Tennessee Oncology — Nashville, Tennessee
- Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville — Nashville, Tennessee
- Mary Crowley Cancer Research — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Neoplasms
- Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer — Tucson, Arizona
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) — Phoenix, Arizona
- Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) — Birmingham, Alabama
Explore by condition: All Endometrial Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.